Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more
Harbin Gloria Pharmaceuticals (002437) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.084x
Based on the latest financial reports, Harbin Gloria Pharmaceuticals (002437) has a cash flow conversion efficiency ratio of 0.084x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥182.89 Million) by net assets (CN¥2.18 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Harbin Gloria Pharmaceuticals - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Harbin Gloria Pharmaceuticals's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Harbin Gloria Pharmaceuticals Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harbin Gloria Pharmaceuticals ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TOWA Corporation
F:TWA
|
N/A |
|
Hunan Friendship&Apollo Commercial Co Ltd
SHE:002277
|
0.015x |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
0.032x |
|
Gray Television Inc
NYSE:GTN-A
|
0.040x |
|
Nippon Light Metal Holdings Company Ltd
F:N9L
|
N/A |
|
Great Wall Enterprise Co Ltd
TW:1210
|
0.061x |
|
Hanwha Corp Preferred
KO:00088K
|
0.032x |
|
China Security & Fire Co Ltd Class A
SHG:600654
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Harbin Gloria Pharmaceuticals (2007–2024)
The table below shows the annual cash flow conversion efficiency of Harbin Gloria Pharmaceuticals from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.97 Billion | CN¥410.94 Million | 0.208x | +29.93% |
| 2023-12-31 | CN¥1.71 Billion | CN¥274.18 Million | 0.160x | +4.39% |
| 2022-12-31 | CN¥1.70 Billion | CN¥261.62 Million | 0.154x | +10.84% |
| 2021-12-31 | CN¥1.98 Billion | CN¥274.18 Million | 0.139x | +1998.19% |
| 2020-12-31 | CN¥1.93 Billion | CN¥12.76 Million | 0.007x | -98.28% |
| 2019-12-31 | CN¥1.59 Billion | CN¥610.37 Million | 0.384x | +45.20% |
| 2018-12-31 | CN¥4.39 Billion | CN¥1.16 Billion | 0.265x | +72.66% |
| 2017-12-31 | CN¥4.25 Billion | CN¥651.80 Million | 0.153x | -40.39% |
| 2016-12-31 | CN¥4.05 Billion | CN¥1.04 Billion | 0.257x | +27.19% |
| 2015-12-31 | CN¥3.47 Billion | CN¥702.05 Million | 0.202x | -6.96% |
| 2014-12-31 | CN¥3.10 Billion | CN¥674.04 Million | 0.217x | +18.87% |
| 2013-12-31 | CN¥2.48 Billion | CN¥453.02 Million | 0.183x | +109.59% |
| 2012-12-31 | CN¥2.36 Billion | CN¥205.89 Million | 0.087x | +49.01% |
| 2011-12-31 | CN¥2.20 Billion | CN¥128.61 Million | 0.059x | +10.24% |
| 2010-12-31 | CN¥2.12 Billion | CN¥112.59 Million | 0.053x | -91.06% |
| 2009-12-31 | CN¥287.53 Million | CN¥170.82 Million | 0.594x | +99.41% |
| 2008-12-31 | CN¥194.04 Million | CN¥57.81 Million | 0.298x | -21.12% |
| 2007-12-31 | CN¥138.36 Million | CN¥52.26 Million | 0.378x | -- |